NATCO Pharma Limited

NSE NATCOPHARM.NS

NATCO Pharma Limited Net Cash Used For Investing Activities for the year ending March 31, 2024: USD -123.81 M

NATCO Pharma Limited Net Cash Used For Investing Activities is USD -123.81 M for the year ending March 31, 2024, a -113.29% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

NATCO Pharma Limited Net Cash Used For Investing Activities for the year ending March 31, 2023 was USD -58.05 M, a -8,216.32% change year over year.
NATCO Pharma Limited Net Cash Used For Investing Activities for the year ending March 31, 2022 was USD -698.01 K, a 95.05% change year over year.
NATCO Pharma Limited Net Cash Used For Investing Activities for the year ending March 31, 2021 was USD -14.11 M, a 36.34% change year over year.
NATCO Pharma Limited Net Cash Used For Investing Activities for the year ending March 31, 2020 was USD -22.16 M, a 74.84% change year over year.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

NSE: NATCOPHARM.NS

NATCO Pharma Limited

CEO	Mr. Rajeev Nannapaneni
IPO Date	Jan. 1, 1996
Location	India
Headquarters	NATCO House
Employees	4,016
Sector	Health Care
Industries Pharmaceuticals

Description

NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. The company also offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina and CHF. The company markets its products in approximately 40 countries, including India, the United States, and internationally. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Key trends

Past 5 years